Latest Posts › DNA

Share:

Docs @ BIO: USPTO Provides Update on Myriad-Mayo Guidance

At last week's BIO International Convention in San Diego, Andrew Hirshfeld, USPTO Deputy Commissioner for Patent Examination Policy, and June Cohan, a Legal Advisor with the USPTO's Office of Patent Legal Administration, took...more

7/2/2014 - DNA Genetic Materials Guidance Update Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Public Comment Section 101 Stem cells USPTO

Top Three Stories of 2013

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/6/2014 - America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto DNA First-to-File First-to-Invent Genetic Materials Genetically Engineered Seed Human Genes Inventors Monsanto Patent Infringement Patent Litigation Patent Reform Patents Pharmaceutical SCOTUS

Top Stories of 2013: #7 to #10

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/2/2014 - Ambry Biotechnology BRCA DNA Human Genes Life Sciences Myriad Patent Litigation Patents Pharmaceutical

Sanofi-Aventis v. Pfizer Inc. (Fed. Cir. 2013)

Last week, in Sanofi-Aventis v. Pfizer Inc., the Federal Circuit affirmed an award of priority to Pfizer by the Board of Patent Appeals and Interferences in an interference involving the cDNA for the human interleukin-13...more

11/15/2013 - DNA Genetic Materials Human Genes Patent Litigation Patent-Eligible Subject Matter Patents Pfizer

23andMe Patent Creates Controversy

A patent issued to 23andMe, Inc. last month has created some controversy, and in response, the biotech company, based in Mountain View, California, has posted its side of the story on the 23andMe blog. The patent, U.S....more

10/9/2013 - 23andMe Biotechnology DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Patents

Authors of Genome Medicine Article Form Genetic Testing Company

In a paper published in March in the journal Genome Medicine, Dr. Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Dr. Christopher Mason of Cornell University contended that due to the...more

8/13/2013 - Biotechnology DNA Genetic Materials Genetic Testing Genome Project Human Genes Medical Research Patents Pharmaceutical

NIH Implements New Policy on HeLa Genomic Data

On Wednesday, the National Institutes of Health (NIH) announced that the agency had reached an understanding with the family of Ms. Henrietta Lacks regarding access to genomic data for the HeLa cell line, which was derived...more

8/9/2013 - Cancer DNA Genetic Materials Genetic Testing Human Genes NIH

NCI Researchers Generate Largest Database of Cancer-specific Genetic Variations

Last month, the American Association for Cancer Research (AACR) announced that researchers at the National Cancer Institute (NCI) had generated a data set of cancer-specific genetic variations, which the researchers were...more

8/7/2013 - Cancer Databases DNA Genetic Materials Human Genes Medical Research

Consumer Watchdog Argues That WARF Stem Cell Patent Is Invalid under ยง 101

Last month, Consumer Watchdog filed its opening brief in an appeal of a Board decision affirming the patentability of U.S. Patent No. 7,029,913, arguing that the claims of the '913 patent are invalid because they cover...more

8/2/2013 - AMP v Myriad DNA Inter Partes Review Proceedings Obviousness Patent-Eligible Subject Matter Patents Stem cells

Senator Leahy Urges NIH to Use March-In Rights on Myriad BRCA Test

On Friday, Sen. Patrick Leahy (D-VT) sent a letter to Dr. Francis Collins, the Director of the National Institutes of Health (NIH), "to urge [the Director] to consider using march-in rights under the Bayh-Dole Act to ensure...more

7/18/2013 - AMP v Myriad Bayh-Dole Act BRCA DNA March-in Myriad NIH Patents USPTO

Consortium Launches Public Database of BRCA Data

On June 13, the Genetic Alliance announced the launch of an initiative to fill the public information gap caused by the lack of available genetic information for the BRCA1 and BRCA2 genes. ...more

7/5/2013 - AMP v Myriad Biotechnology BRCA DNA Genetic Materials Genetic Services Genetic Testing Patents Pharmaceutical

Reaction to Supreme Court's Decision in AMP v. Myriad

It has been just over two weeks since the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., holding that a naturally occurring DNA segment is a product of nature and not patent...more

7/2/2013 - ACLU AIPLA AMP v Myriad DNA Myriad Patent-Eligible Subject Matter Patents Product of Nature Doctrine

Supreme Court Issues Decision in AMP v. Myriad -- Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

In a much anticipated decision, the Supreme Court issued its opinion this morning in Association for Molecular Pathology v. Myriad Genetics, Inc. In an opinion by Justice Thomas, joined by Chief Justice Roberts, Justices...more

6/14/2013 - AMP v Myriad Biotechnology DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

USPTO Issues Memo on AMP v. Myriad to Examining Corps

On the same day that the Supreme Court handed down its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Patent and Trademark Office issued a one-page memorandum to its Patent Examining Corps...more

6/14/2013 - AMP v Myriad DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS USPTO

A Primer on Claim Construction -- Comments on Dr. Mason's Response

Yesterday, we posted a response from Dr. Chris Mason of Cornell University to a recent Patent Docs post and an article posted by Dr. Chris Holman on Holman's Biotech IP Blog. Dr. Mason co-authored an article in the current...more

4/12/2013 - Claim Construction DNA Gene Patenting Human Genes Patents

Revisiting Genome Medicine Article on "Pervasive Sequence Patents" That "Cover the Entire Human Genome"

Last week, we reported on an article in the current issue of Genome Medicine which contends that due to the non-specificity of sequence uniqueness across the genome and the broad scope of claims to nucleotide sequences, the...more

4/9/2013 - DNA Gene Patenting Genome Project Patents

Genome Medicine Article Calls for Limits on Patenting of Existing Nucleotide Sequences

In an article published in the current issue of Genome Medicine, Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Christopher Mason of Cornell University contend that due to the non-specificity of...more

4/3/2013 - DNA Human Genes Myriad Patent-Eligible Subject Matter Patents

United States Asks Supreme Court to Affirm on cDNA, Reverse on Isolated, Unmodified DNA

In an amicus brief filed last month in Association for Molecular Pathology v. Myriad Genetics, Inc., the United States asks the Supreme Court to affirm the judgment of the Federal Circuit that cDNA is patent-eligible and...more

2/13/2013 - DNA Myriad Patent-Eligible Subject Matter Patents SCOTUS

Top Three Stories of 2012

Reflecting upon the events of the past twelve months, Patent Docs presents its sixth annual list of top biotech/pharma patent stories. For 2012, we identified fifteen stories that were covered on Patent Docs last year that...more

1/4/2013 - America Invents Act DNA Human Genes Mayo v. Prometheus Myriad Patent Reform Patent-Eligible Subject Matter

Top Stories of 2012: #4 to #7

Reflecting upon the events of the past twelve months, Patent Docs presents its sixth annual list of top biotech/pharma patent stories. For 2012, we identified fifteen stories that were covered on Patent Docs last year that...more

1/3/2013 - Biotechnology DNA FDA Infringement Patent Exhaustion Patents Pharmaceutical Safe Harbors

20 Results
|
View per page
Page: of 1